PDB: 1FG9; “Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex”. Structure8 (9): 927–936. (September 2000). doi:10.1016/S0969-2126(00)00184-2. PMID10986460.
“The heparan sulfate binding sequence of interferon-gamma increased the on rate of the interferon-gamma-interferon-gamma receptor complex formation”. The Journal of Biological Chemistry273 (18): 10919–10925. (May 1998). doi:10.1074/jbc.273.18.10919. PMID9556569.
“Interferon-gamma binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule”. FEBS Letters280 (1): 152–154. (March 1991). doi:10.1016/0014-5793(91)80225-R. PMID1901275.
“Interferon-gamma: an overview of signals, mechanisms and functions”. Journal of Leukocyte Biology75 (2): 163–189. (February 2004). doi:10.1189/jlb.0603252. PMID14525967.
“Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity”. Cell175 (6): 1634–1650.e17. (November 2018). doi:10.1016/j.cell.2018.09.042. PMID30433869.
“Effects of products of activated leukocytes (lymphokines and monokines) on the growth of malignant trophoblast cells in vitro”. American Journal of Obstetrics and Gynecology158 (1): 199–203. (January 1988). doi:10.1016/0002-9378(88)90810-1. PMID2447775.
“Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation”. Journal of Biotechnology240: 48–60. (December 2016). doi:10.1016/j.jbiotec.2016.10.022. PMID27794496.
“Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease”. Drugs43 (1): 111–122. (January 1992). doi:10.2165/00003495-199243010-00008. PMID1372855.
“The use of interferon-gamma therapy in chronic granulomatous disease”. Recent Patents on Anti-Infective Drug Discovery3 (3): 225–230. (November 2008). doi:10.2174/157489108786242378. PMID18991804.
“Drug Marketing. The line between scientific uncertainty and promotion of snake oil”. BMJ347: f5687. (September 2013). doi:10.1136/bmj.f5687. PMID24055923.
“Open-label pilot study of interferon gamma-1b in Friedreich ataxia”. Acta Neurologica Scandinavica132 (1): 7–15. (July 2015). doi:10.1111/ane.12337. PMID25335475.
“Atopic dermatitis: systemic immunosuppressive therapy”. Seminars in Cutaneous Medicine and Surgery27 (2): 151–155. (June 2008). doi:10.1016/j.sder.2008.04.004. PMID18620137.
“Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis”. Annals of Allergy, Asthma & Immunology80 (3): 263–268. (March 1998). doi:10.1016/S1081-1206(10)62968-7. PMID9532976.
“Recombinant interferon gamma therapy for atopic dermatitis”. Journal of the American Academy of Dermatology28 (2 Pt 1): 189–197. (February 1993). doi:10.1016/0190-9622(93)70026-p. PMID8432915.
“Improved therapeutic efficacy of mammalian expressed-recombinant interferon gamma against ovarian cancer cells”. Experimental Cell Research359 (1): 20–29. (October 2017). doi:10.1016/j.yexcr.2017.08.014. PMID28803068.
“Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex”. Structure8 (9): 927–936. (September 2000). doi:10.1016/S0969-2126(00)00184-2. PMID10986460.
“Interaction between the components of the interferon gamma receptor complex”. The Journal of Biological Chemistry270 (36): 20915–20921. (September 1995). doi:10.1074/jbc.270.36.20915. PMID7673114.
“Investigations of seborrheic dermatitis. Part I. The role of selected cytokines in the pathogenesis of seborrheic dermatitis”. Postepy Higieny I Medycyny Doswiadczalnej66: 843–847. (November 2012). doi:10.5604/17322693.1019642. PMID23175340.
“Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner”. The Journal of General Virology91 (Pt 3): 591–598. (March 2010). doi:10.1099/vir.0.016964-0. PMID19906941.
“Immune control of herpes simplex virus during latency”. Current Opinion in Immunology16 (4): 463–469. (August 2004). doi:10.1016/j.coi.2004.05.003. PMID15245740.
“Human interferon-gamma mRNA autoregulates its translation through a pseudoknot that activates the interferon-inducible protein kinase PKR”. Cell108 (2): 221–232. (January 2002). doi:10.1016/S0092-8674(02)00616-5. PMID11832212.
“Release of virus inhibitor from tuberculin-sensitized peritoneal cells stimulated by antigen”. Journal of Immunology105 (5): 1068–1071. (November 1970). PMID4321289.
PDB: 1FG9; “Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex”. Structure8 (9): 927–936. (September 2000). doi:10.1016/S0969-2126(00)00184-2. PMID10986460.
“The heparan sulfate binding sequence of interferon-gamma increased the on rate of the interferon-gamma-interferon-gamma receptor complex formation”. The Journal of Biological Chemistry273 (18): 10919–10925. (May 1998). doi:10.1074/jbc.273.18.10919. PMID9556569.
“Interferon-gamma binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule”. FEBS Letters280 (1): 152–154. (March 1991). doi:10.1016/0014-5793(91)80225-R. PMID1901275.
“Interferon-gamma: an overview of signals, mechanisms and functions”. Journal of Leukocyte Biology75 (2): 163–189. (February 2004). doi:10.1189/jlb.0603252. PMID14525967.
“Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity”. Cell175 (6): 1634–1650.e17. (November 2018). doi:10.1016/j.cell.2018.09.042. PMID30433869.
“Effects of products of activated leukocytes (lymphokines and monokines) on the growth of malignant trophoblast cells in vitro”. American Journal of Obstetrics and Gynecology158 (1): 199–203. (January 1988). doi:10.1016/0002-9378(88)90810-1. PMID2447775.
“Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation”. Journal of Biotechnology240: 48–60. (December 2016). doi:10.1016/j.jbiotec.2016.10.022. PMID27794496.
“Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease”. Drugs43 (1): 111–122. (January 1992). doi:10.2165/00003495-199243010-00008. PMID1372855.
“The use of interferon-gamma therapy in chronic granulomatous disease”. Recent Patents on Anti-Infective Drug Discovery3 (3): 225–230. (November 2008). doi:10.2174/157489108786242378. PMID18991804.
“Drug Marketing. The line between scientific uncertainty and promotion of snake oil”. BMJ347: f5687. (September 2013). doi:10.1136/bmj.f5687. PMID24055923.
“Open-label pilot study of interferon gamma-1b in Friedreich ataxia”. Acta Neurologica Scandinavica132 (1): 7–15. (July 2015). doi:10.1111/ane.12337. PMID25335475.
“Atopic dermatitis: systemic immunosuppressive therapy”. Seminars in Cutaneous Medicine and Surgery27 (2): 151–155. (June 2008). doi:10.1016/j.sder.2008.04.004. PMID18620137.
“Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis”. Annals of Allergy, Asthma & Immunology80 (3): 263–268. (March 1998). doi:10.1016/S1081-1206(10)62968-7. PMID9532976.
“Recombinant interferon gamma therapy for atopic dermatitis”. Journal of the American Academy of Dermatology28 (2 Pt 1): 189–197. (February 1993). doi:10.1016/0190-9622(93)70026-p. PMID8432915.
“Improved therapeutic efficacy of mammalian expressed-recombinant interferon gamma against ovarian cancer cells”. Experimental Cell Research359 (1): 20–29. (October 2017). doi:10.1016/j.yexcr.2017.08.014. PMID28803068.
“Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex”. Structure8 (9): 927–936. (September 2000). doi:10.1016/S0969-2126(00)00184-2. PMID10986460.
“Interaction between the components of the interferon gamma receptor complex”. The Journal of Biological Chemistry270 (36): 20915–20921. (September 1995). doi:10.1074/jbc.270.36.20915. PMID7673114.
“Investigations of seborrheic dermatitis. Part I. The role of selected cytokines in the pathogenesis of seborrheic dermatitis”. Postepy Higieny I Medycyny Doswiadczalnej66: 843–847. (November 2012). doi:10.5604/17322693.1019642. PMID23175340.
“Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner”. The Journal of General Virology91 (Pt 3): 591–598. (March 2010). doi:10.1099/vir.0.016964-0. PMID19906941.
“Immune control of herpes simplex virus during latency”. Current Opinion in Immunology16 (4): 463–469. (August 2004). doi:10.1016/j.coi.2004.05.003. PMID15245740.
“Human interferon-gamma mRNA autoregulates its translation through a pseudoknot that activates the interferon-inducible protein kinase PKR”. Cell108 (2): 221–232. (January 2002). doi:10.1016/S0092-8674(02)00616-5. PMID11832212.
PDB: 1FG9; “Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex”. Structure8 (9): 927–936. (September 2000). doi:10.1016/S0969-2126(00)00184-2. PMID10986460.